Development of an ASBI may not only provide a potential new treatment for AD and the condition that often precedes it, Mild Cognitive Impairment (MCI) due to AD, but may do so with reduced off-target effects as compared to BACE1 inhibitors that have been clinically tested and are not selective for APP. The gene discussed is BACE1; the disease is Alzheimer disease.